Last updated: March 7, 2026
What are the core details of the case?
Bayer HealthCare Pharmaceuticals Inc. filed suit against Perrigo UK FINCO Limited Partnership in the U.S. District Court for the District of New Jersey (Case No. 1:18-cv-00261). The dispute centers on patent infringement related to non-prescription dermatological and gastrointestinal pharmaceutical products.
Timeline and procedural background
- Filing date: January 16, 2018
- Claims: Bayer alleges Perrigo infringed on U.S. Patent No. 9,399,036, issued August 23, 2016, which covers formulations for topical and oral over-the-counter (OTC) products.
- Defendant response: Perrigo filed a motion to dismiss in March 2018, challenging the patent's validity and alleging non-infringement.
- District court decision: The court denied Perrigo’s motion in August 2018, allowing the case to proceed to trial.
Legal claims
- Patent infringement under 35 U.S.C. § 271
- Patent validity under 35 U.S.C. § 282
- Allegations that Perrigo's products infringe Bayer’s patent rights
What are the key claims and defenses?
Bayer's claims
- Patent infringement: Bayer asserts Perrigo's OTC products use formulations covered by the '036 patent.
- Damages: Bayer seeks injunctive relief and monetary compensation for infringement.
Perrigo's defenses
- Patent invalidity: Perrigo argues the patent lacks novelty and non-obviousness.
- Non-infringement: Perrigo contends its products do not meet all patent claims sufficiently to constitute infringement.
- Patent unenforceability: Perrigo claims inequitable conduct during patent prosecution.
What are the significant legal issues?
Patent validity
- The '036 patent covers specific compositions and methods that Perrigo claims are obvious based on prior art references.
- Bayer defends novelty, highlighting the unique combination of ingredients and manufacturing process.
Infringement scope
- Details on Perrigo’s formulations and whether they fall within the claims of the patent are central.
- The court considers whether minimal differences exempt Perrigo’s products from infringement, or if they fall within the patent’s scope.
Procedural developments
- The court's denial of Perrigo's motion to dismiss indicates sufficient factual allegations supporting Bayer’s claims.
- Discovery phase revealed that Perrigo's product formulations closely resemble Bayer's patented compositions, strengthening Bayer's infringement case.
Patent litigation outcomes
- The case remains unresolved; part of ongoing dispute resolution efforts, including potential settlement negotiations.
- No final judgment or settlement has been publicly announced as of 2023.
How does this case compare to similar patent disputes?
| Aspect |
Bayer v. Perrigo |
Typical OTC patent litigation |
| Patent type |
Composition and formulation patent |
Often process or delivery method patents |
| Defendant's argument |
Patent invalidity, non-infringement |
Common defenses in patent cases |
| Case status |
Pending or in early resolution stages |
Many such cases settle before trial |
| Key legal focus |
Patent validity, infringement scope |
Similar focus, with added emphasis on prior art defenses |
What are the potential implications?
- For Bayer: Success could establish enforceability of its formulations for OTC medications, strengthening patent rights.
- For Perrigo: If found infringing, Perrigo might face injunctions and damages, affecting product offerings.
- Industry impact: Clarifies patentability of combination formulations in OTC drugs and the validity challenges they face.
Closing notes
The case exemplifies the high stakes in patent disputes over OTC products. The legal focus remains on formulation patent strength and infringement scope. As legal proceedings continue, outcomes could influence patent strategies and formulation disclosures in the OTC pharmaceutical industry.
Key Takeaways
- Bayer alleges Perrigo infringed a formulation patent covering OTC dermatological and gastrointestinal products.
- The court’s denial of Perrigo’s motion to dismiss indicates the case’s substantive issues deserve full consideration.
- Patent validity challenges hinge on prior art and claim scope.
- The case highlights the importance of detailed patent prosecution and product formulation disclosures.
- Ongoing proceedings may result in settlement or further legal rulings influencing OTC patent landscape.
FAQs
1. Can Perrigo avoid infringement by slightly modifying its products?
Yes, if modifications fall outside the scope of Bayer's patent claims, Perrigo may avoid infringement. Courts assess whether the accused product meets each claim element.
2. How does patent invalidity influence patent infringement cases?
Proving a patent invalid typically ends the case in favor of the defendant. Validity is often challenged based on prior art, obviousness, or patent prosecution issues.
3. What damages can Bayer recover if successful?
Bayer could seek monetary damages, including lost profits and reasonable royalties. Injunctive relief may also restrict Perrigo from selling infringing products.
4. How long do patent infringement lawsuits usually last?
Litigation durations vary; many cases take 2-4 years to resolve, though some settle earlier.
5. Could this case impact OTC formulations industry-wide?
Yes, favorable rulings could reinforce patent protection for OTC formulations, influencing industry R&D and patent filing strategies.
References
[1] United States Patent and Trademark Office. (2016). Patent No. 9,399,036.
[2] Bayer HealthCare Pharmaceuticals Inc. v. Perrigo UK FINCO Limited Partnership, No. 1:18-cv-00261 (D.N.J. filed Jan. 16, 2018).
[3] Court filings and judicial opinions from docket entries (available through PACER or public court records).
